High sensitivity and specificity were identified for the d-signature to differentiate CRC from CRA, which was of great significance in clinical practice, especially when it comes to early-stage (stage I–II) CRC or CEA-negative CRC. Here, CEACAM5 is linked to colorectal carcinoma.